Brazil conditionally clears Takeda drug portfolio purchase
Shutterstock/Michael Vi
Brazil’s competition authority has greenlit local drugmaker Hypera Pharma’s bid to purchase a portfolio of medications from Takeda Pharmaceutical after the company offered a “fix-it-first” structural remedy.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now